Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/10990
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
Romaniello, Donatella | Marrocco, Ilaria | Belugali Nataraj, Nishanth | Ferrer, Irene | Drago-Garcia, Diana | Vaknin, Itay | Oren, Roni | Lindzen, Moshit | Ghosh, Soma | Kreitman, Matthew | Kittel, Jeanette Clarissa | Gaborit, Nadege | Bergado Baez, Gretchen | Sanchez, Belinda | Eilam, Raya | Pikarsky, Eli | Yarden, Yosef | Paz Ares, Luis Gonzaga CNIO
Cancers (Basel) . 2020;12(9):E2394.
Although two growth factor receptors, EGFR and HER2, are amongst the best targets for cancer treatment, no agents targeting HER3, their kinase-defective family member, have so far been approved. Because emergence of resistance of lung tumors to EGFR kinase inhibitors (EGFRi) associates with compensatory up-regulation of HER3 and several secreted forms, we anticipated that blocking HER3 would prevent resistance. As demonstrated herein, a neutralizing anti-HER3 antibody we generated can clear HER3 from the cell surface, as well as reduce HER3 cleavage by ADAM10, a surface metalloproteinase. When combined with a kinase inhibitor and an anti-EGFR antibody, the antibody completely blocked patient-derived xenograft models that acquired resistance to EGFRi. We found that the underlying mechanism involves posttranslational downregulation of HER3, suppression of MET and AXL upregulation, as well as concomitant inhibition of AKT signaling and upregulation of BIM, which mediates apoptosis. Thus, although HER3 is nearly devoid of kinase activity, it can still serve as an effective drug target in the context of acquired resistance. Because this study simulated in animals the situation of patients who develop resistance to EGFRi and remain with no obvious treatment options, the observations presented herein may warrant clinical testing.